Compare · BKHA vs MRNA
BKHA vs MRNA
Side-by-side comparison of Black Hawk Acquisition Corporation (BKHA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BKHA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $20.12B.
- Over the past year, BKHA is up 10.4% and MRNA is up 84.6% - MRNA leads by 74.2 points.
- MRNA has been more active in the news (8 items in the past 4 weeks vs 2 for BKHA).
- MRNA has more recent analyst coverage (25 ratings vs 0 for BKHA).
- Company
- Black Hawk Acquisition Corporation
- Moderna Inc.
- Price
- $11.65+0.52%
- $50.74-3.98%
- Market cap
- -
- $20.12B
- 1M return
- +0.52%
- -5.22%
- 1Y return
- +10.43%
- +84.64%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2018
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest BKHA
- SEC Form 10-Q filed by Black Hawk Acquisition Corporation
- SEC Form NT 10-Q filed by Black Hawk Acquisition Corporation
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by Black Hawk Acquisition Corporation
- SEC Form NT 10-K filed by Black Hawk Acquisition Corporation
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Leadership Update
- Amendment: SEC Form S-4/A filed by Black Hawk Acquisition Corporation
Latest MRNA
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
- Moderna to Present at Upcoming Conferences in May 2026
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
- SEC Form 4 filed by Mock James M
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- SEC Form DEF 14A filed by Moderna Inc.